Hormone therapy linked to lower risk at one disability threshold
In women with multiple sclerosis, current hormone use was linked to a lower relative rate of reaching one disability threshold than nonuse (adjusted hazard ratio 0.70).
Dose-response
Limit: Unmeasured menopausal status could account for differences between hormone users and nonusers
Edited by Boris Djordjevic · AgingResearch.News
A Swedish registry-based observational study followed 7,623 women with multiple sclerosis, aged 40 to 60 at entry, through 2025. Of these, 1,192 started systemic hormone replacement therapy, which delivers hormones throughout the body. Researchers accounted for age, multiple sclerosis medicines and other measured differences.
Current hormone use was associated with a lower rate of sustained disability reaching 4.0 on the Expanded Disability Status Scale, which rates disability in multiple sclerosis. The adjusted hazard ratio, comparing rates over time with nonuse, was 0.70. Hormone use was not associated with reaching the higher, more severe 6.0 threshold or with recurring relapses, episodes of renewed disease activity. Dose categories showed no consistent pattern of stronger associations at higher doses.
Why it matters
For women aging with multiple sclerosis, a key question is whether menopausal hormone therapy is linked to the course of their disease.
Caveats
This observational preprint cannot establish cause and effect and has not been peer-reviewed. Menopausal status was unmeasured, and the cohort included only women aged 40 to 60 at entry.
The paper
Hormone Replacement Therapy and Disability Progression in Women with Multiple Sclerosis
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
medRxiv, Oct 23, 2026, Open access, Preprint, not peer-reviewed
